Equities

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)123.61
  • Today's Change4.53 / 3.80%
  • Shares traded868.11k
  • 1 Year change-3.61%
  • Beta0.5716
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

  • Revenue in USD (TTM)3.99bn
  • Net income in USD463.16m
  • Incorporated2005
  • Employees2.80k
  • Location
    Jazz Pharmaceuticals PLCFifth FlWaterloo Exchange, Waterloo RoadDUBLIN 4IrelandIRL
  • Phone+353 16347800
  • Fax+353 16347850
  • Websitehttps://www.jazzpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
JAZZ:NSQ since
announced
Transaction
value
Redx Pharma PLC-KRAS Inhibitor ProgramAnnounced07 Feb 202407 Feb 2024Announced-0.88%--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Prestige Consumer Healthcare Inc1.11bn205.95m3.98bn570.0019.582.2916.773.594.114.1122.1435.030.3343.136.901,948,525.006.193.696.423.8455.2156.7918.5412.192.105.680.37790.00-0.212.89354.34---1.84--
Organon & Co6.41bn1.30bn4.13bn10.00k3.188.382.650.64465.045.0424.811.910.53942.083.85640,900.0010.9516.5314.0820.9758.2665.1220.3026.791.212.730.94678.251.44-8.5211.56-13.8320.91--
Axsome Therapeutics Inc291.49m-308.55m4.32bn545.00--41.86--14.83-6.51-6.516.152.150.50262.313.11534,842.20-53.20-64.55-71.90-82.2390.30---105.85-227.052.40-79.610.6409--440.80---27.84--77.86--
BridgeBio Pharma Inc219.12m-453.82m5.09bn550.00------23.25-2.64-2.641.24-5.810.3376----398,407.30-71.11-72.44-89.59-89.7298.9194.41-210.62-1,225.66---9.632.70---88.02---33.67---40.94--
ADMA Biologics Inc330.24m34.79m5.35bn624.00160.8728.00123.9216.190.14060.14061.410.80790.91811.049.88529,237.609.67-24.8010.99-28.0046.1217.4010.53-51.312.804.590.4105--67.5972.3457.15--18.91--
Avidity Biosciences Inc10.60m-252.45m5.50bn253.00--4.18--518.75-2.95-2.950.123111.170.0108--17.9241,893.28-25.78-31.61-27.61-34.45-----2,381.82-1,540.50----0.00--3.6490.71-21.97--143.89--
Corcept Therapeutics Incorporated628.56m141.82m6.24bn352.0046.949.7443.689.931.271.275.646.120.91211.2613.321,785,668.0020.5821.1725.1023.8598.4498.5222.5627.233.64--0.000.0020.0413.934.667.08-14.15--
Elanco Animal Health Inc4.45bn205.00m6.96bn9.30k34.431.077.961.560.40870.40878.9913.200.32241.215.09478,924.701.48-3.271.64-3.6554.6954.284.60-11.531.310.98830.4005--0.1367.57-1,478.21--2.74--
Jazz Pharmaceuticals PLC3.99bn463.16m7.63bn2.80k17.411.796.841.917.107.1060.2769.010.34040.73715.911,425,969.003.971.484.461.6289.3788.7911.654.263.742.820.59440.004.7815.19285.14-1.49-20.04--
Halozyme Therapeutics, Inc.947.36m392.47m7.76bn373.0020.1817.1316.378.193.023.027.303.560.47241.303.772,539,826.0019.5718.2220.7321.9782.0979.0541.4339.369.15--0.76870.0025.6240.4339.31--26.82--
Roivant Sciences Ltd158.30m4.74bn8.78bn845.002.131.611.8955.455.575.570.19797.350.03670.80182.71187,340.80106.95--126.66--90.32--2,916.27--27.75--0.052--103.65--487.06------
Intra-Cellular Therapies Inc613.73m-86.37m9.68bn610.00--8.45--15.77-0.8595-0.85956.1010.800.60111.424.941,006,112.00-8.46-38.27-9.74-42.7792.30---14.07-128.427.51--0.00--85.51--45.49---7.22--
Catalent Inc4.42bn-413.00m10.78bn16.90k--3.04140.052.44-2.27-2.2724.3319.570.44824.923.27261,656.80-4.190.0124-4.800.01421.8228.93-9.340.02781.930.78140.5821--2.7711.71-307.42--8.44--
Data as of Nov 08 2024. Currency figures normalised to Jazz Pharmaceuticals PLC's reporting currency: US Dollar USD

Institutional shareholders

41.12%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20246.16m9.97%
BlackRock Fund Advisorsas of 30 Jun 20245.39m8.73%
LSV Asset Managementas of 30 Jun 20242.48m4.02%
Capital Research & Management Co. (World Investors)as of 30 Jun 20242.02m3.27%
SSgA Funds Management, Inc.as of 30 Jun 20242.02m3.27%
Pacer Advisors, Inc.as of 30 Jun 20241.82m2.95%
Vestal Point Capital LPas of 30 Jun 20241.50m2.43%
Polaris Capital Management LLCas of 30 Jun 20241.38m2.23%
JPMorgan Investment Management, Inc.as of 30 Jun 20241.36m2.20%
The Baupost Group LLCas of 30 Jun 20241.27m2.06%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.